Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

SonicAllStars Jan. 12 at 1:38 AM

$BIIB listed on OTC or nasdaq

0 · Reply

MoneyGroupLLC Jan. 11 at 11:43 AM

Enter: $BIIB Calls Strike Price: $190 Expiry Date: FEB 06 2026 Buy in Price: $6.30 - $8.50 Sell Price: $14.43 Profit : +129% (Turn every $1 into $2.29) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

WallStreetBuyDip Jan. 10 at 5:01 AM

$BIIB Massive volume spike on Jan 7 with 2.1M shares traded as price hit $186.91. Followed by a slight decrease in volume on Jan 8 at 1.6M shares traded with a price of $186. Waiting for a lower H% before considering entry.

0 · Reply

macroaxis Jan. 9 at 10:40 PM

$BIIB - Option Volatility Signal: Biogen Pin Risk Easing – Potential Opportunity Ahead https://www.macroaxis.com/stock-options/BIIB/Biogen-Inc?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

dogDazeSummer Jan. 9 at 10:34 PM

6/3/25 $MRK offers $3B *before P3 HS data* $48.50 / share, declined. 9/26/25 Moonlake announces data from (2) P3 HS ‘well powered’ studies conducted in different global regions, closing trade $61.99 9/29/25 opens at $6.97, down 92% due to high placebo in 1 of HS studies. 1/8/26, FDA allows Moonlake to disregard P3 study w high placebo rate. 1/9/26 closed $18.26, Wedbush announces “high likelihood approval”. 1/3 buyout value pre data & pre FDA guidance 1/12/26 ? https://www.fiercebiotech.com/biotech/merck-made-3b-plus-offer-moonlake-and-could-revive-interest-late-phase-biotech-ft Merck $BIIB $AMGN want into HS / C5a/ anti inflammatory w focus on China, aka $IFRX $MLTX “Merck has struck a series of deals to bring molecules discovered in China to Western markets, but Davis dismissed the idea the company is leaning more toward the Asian country than anywhere else. The CEO said “it just happens to be that the recency bias in the last couple of deals” has skewed toward China.

2 · Reply

HScottMatusow Jan. 9 at 10:22 PM

Continued from last post; Self-dealing bs is common place in #Biotech. A deal with $NVS grants upper management here cushy options and a position in NVS, whereas #RHHBY and $BIIB would likely only offer an all cash dissolve deal and no future options for $QURE seniors? Again, read the amended change of control/restructure deal approved in June of this year, a long with this year being the first year the company DID NOT AWARD performance incentive option grants (no awards past march) for hitting arguably, the best data ever seen in neurology? And again, out of the last 20 #biotech acquisitions, only 2 has language exactly like $QURE's, AND BOTH WERE ACQUIRED BY $NVS. Coincidence? LOL!! Does anyone out there ever think anymore for themselves. STOP sniffing and kissing $QURE BOD and CEO ass, they are the bad guys, not the #FDA

1 · Reply

hegdaom Jan. 9 at 9:39 PM

$CAPR Can anyone in two to three coherent sentences share here. Whats the argument for a short case? $PFE $LLY $MRK $BIIB $LLY

2 · Reply

Chartist0_0 Jan. 9 at 12:22 PM

$BIIB this is a stock where wake up early, check the preopen and see it’s up 70$ points.

1 · Reply

MoneyGroupLLC Jan. 9 at 11:44 AM

Enter: $BIIB Calls Strike Price: $188 Expiry Date: JAN 30 2026 Buy in Price: $1.59 - $1.67 Sell Price: $3.39 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Jessypenny Jan. 9 at 9:56 AM

Biotech Breakout Alert: The Momentum Club The sector is on fire as we head into JPM week! While the $IBB hits new highs, these 4 names are leading the charge with relentless 52-week high streaks: $DRTS — The star of the week. 4 consecutive days of 52-week highs! With the FDA PMA submission live and ASCO GI data validating the pancreatic platform, Alpha Tau is entering an era of unprecedented growth. Institutional accumulation is undeniable. $BIIB — 4-day streak. Reached $186.91 yesterday. Massive confidence following the VALOR study updates and stabilized base business. $REGN — 3-day streak. Hit $812.27. Analysts are raising targets to $1,000+ as Dupixent growth shows no signs of slowing. $NTRA — 4-day streak. Touching $254.40. The oncology diagnostics king is benefiting from a massive shift toward personalized medicine. The "January Effect" is real. $DRTS is leading the small-cap charge while the giants provide the floor.

0 · Reply

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

STOK

Jan 5, 2026, 8:00 PM EST - 6 days ago

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Dec 30, 2025, 8:57 AM EST - 12 days ago

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge

Dec 22, 2025, 11:20 AM EST - 20 days ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Dec 9, 2025, 7:00 AM EST - 4 weeks ago

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Dec 8, 2025, 6:30 PM EST - 4 weeks ago

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 5, 2025, 9:00 AM EST - 5 weeks ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

STOK

Dec 5, 2025, 9:00 AM EST - 5 weeks ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 3, 2025, 2:03 PM EST - 5 weeks ago

Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:40 PM EST - 5 weeks ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025, 3:43 PM EST - 5 weeks ago

Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:30 AM EST - 5 weeks ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 weeks ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

STOK

Nov 27, 2025, 7:30 PM EST - 6 weeks ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Nov 25, 2025, 7:30 AM EST - 6 weeks ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 24, 2025, 11:17 AM EST - 6 weeks ago

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Nov 24, 2025, 7:30 AM EST - 6 weeks ago

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Nov 24, 2025, 7:30 AM EST - 6 weeks ago

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Nov 24, 2025, 7:25 AM EST - 6 weeks ago

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

NVO

Nov 21, 2025, 1:13 PM EST - 7 weeks ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY

Nov 20, 2025, 7:30 AM EST - 7 weeks ago

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference

Nov 18, 2025, 8:25 AM EST - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN GILD GSK JNJ LLY

Nov 17, 2025, 7:30 AM EST - 7 weeks ago

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Nov 17, 2025, 7:30 AM EST - 7 weeks ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

STOK

Nov 17, 2025, 6:00 AM EST - 7 weeks ago

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Nov 14, 2025, 4:05 PM EST - 2 months ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS

Nov 13, 2025, 6:41 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript

Nov 13, 2025, 6:30 PM EST - 2 months ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom

Nov 10, 2025, 5:01 PM EST - 2 months ago

Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript

Nov 3, 2025, 7:30 AM EST - 2 months ago

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Oct 30, 2025, 9:16 PM EDT - 2 months ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:40 AM EDT - 2 months ago

Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise

Oct 30, 2025, 6:11 AM EDT - 2 months ago

Biogen trims annual profit forecast on expected hit from R&D-related charges

Oct 26, 2025, 7:30 PM EDT - 2 months ago

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease

Oct 24, 2025, 8:30 AM EDT - 2 months ago

Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion

Oct 24, 2025, 7:30 AM EDT - 2 months ago

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Oct 22, 2025, 7:30 AM EDT - 2 months ago

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Oct 13, 2025, 7:30 PM EDT - 3 months ago

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”

Oct 9, 2025, 4:30 PM EDT - 3 months ago

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Oct 9, 2025, 4:30 PM EDT - 3 months ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

STOK

Oct 9, 2025, 10:54 AM EDT - 3 months ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 6, 2025, 4:30 PM EDT - 3 months ago

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BMY GILD

Oct 3, 2025, 8:50 AM EDT - 3 months ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 1, 2025, 5:48 PM EDT - 3 months ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BMY IBB LLY MRK MRNA PFE

Sep 28, 2025, 7:30 PM EDT - 3 months ago

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

Sep 26, 2025, 12:21 PM EDT - 3 months ago

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

ABBV LLY MRK PFE BMY

Sep 24, 2025, 2:17 PM EDT - 3 months ago

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 7:30 AM EDT - 3 months ago

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia

Sep 23, 2025, 4:41 PM EDT - 3 months ago

US FDA declines to approve higher-dose of Biogen's genetic disorder drug

SonicAllStars Jan. 12 at 1:38 AM

$BIIB listed on OTC or nasdaq

0 · Reply

MoneyGroupLLC Jan. 11 at 11:43 AM

0 · Reply

WallStreetBuyDip Jan. 10 at 5:01 AM

0 · Reply

macroaxis Jan. 9 at 10:40 PM

$BIIB - Option Volatility Signal: Biogen Pin Risk Easing – Potential Opportunity Ahead https://www.macroaxis.com/stock-options/BIIB/Biogen-Inc?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

dogDazeSummer Jan. 9 at 10:34 PM

2 · Reply

HScottMatusow Jan. 9 at 10:22 PM

1 · Reply

hegdaom Jan. 9 at 9:39 PM

$CAPR Can anyone in two to three coherent sentences share here. Whats the argument for a short case? $PFE $LLY $MRK $BIIB $LLY

2 · Reply

Chartist0_0 Jan. 9 at 12:22 PM

$BIIB this is a stock where wake up early, check the preopen and see it’s up 70$ points.

1 · Reply

MoneyGroupLLC Jan. 9 at 11:44 AM

0 · Reply

Jessypenny Jan. 9 at 9:56 AM

0 · Reply

dogDazeSummer Jan. 8 at 8:06 PM

$IFRX lrnk “Getting Lean and Focusing on Izicopan in HS; Cash Runway Extended to Mid-2027 InflaRx has also initiated a workforce reduction of 30% and substantial reductions, including in Gohibic commercial spending. As we outlined in our downgrade note, while we were intrigued by the HS data, we have concerns with the cash runway and the next major inflection point. Thus, we view the reduction in force as *a difficult but prudent decision*. These moves are expected to extend the cash runway to mid-2027 (versus into 2027 previously). ● Partnering opportunities remain intact. The company will continue to review partnering opportunities for Gohibic in the US and Europe. Moreover, as disclosed last week InflaRx anticipates meeting with the FDA to determine a potential development path forward for vilobelimab in (PG). We note that Biogen, $BIIB (OP Goodman) recently paid $70M upfront to Vanqua Bio (Private) for a preclinical oral C5aR1 antagonist (also up to $990M ..)…”

0 · Reply

Chartist0_0 Jan. 8 at 7:56 PM

$BIIB 250$ in March

0 · Reply

IN0V8 Jan. 8 at 4:34 PM

$BIIB Opportunity Mizuho raises target price to $207 from $177 RBC raises target price to $220 from $210 Truist Securities raises target price to $190 from $142

0 · Reply

MoneyGroupLLC Jan. 7 at 9:34 PM

Enter: $BIIB Calls Strike Price: $185 Expiry Date: JAN 30 2026 Buy in Price: $2.85 - $5.00 Sell Price: $6.18 Profit : +117% (Turn every $1 into $2.17) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

dogDazeSummer Jan. 7 at 7:34 PM

$IFRX wishing the company the very best next week at $JPM global biotech, the biggest event of the year. Energy/ positive vibes make a difference in their collective activities and performance. This is the very reason I purge all intentionally negative thoughts / foolish comments and feedback. It’s contagious and spreads. Although I always appreciate opposing views and different opinions, the energy we share makes a difference. May 2026 be the best year ever for Inflarx, Tom, Neil’s and all employees to finally cash a winning ticket. $AMGN $BIIB $LLY all know it’s a winning MOA: $4B, $1.1b, $1.0b pending.

2 · Reply

JFDI Jan. 7 at 4:22 PM

$BIIB stair stepping

0 · Reply

Albino_Trader123 Jan. 7 at 2:44 PM

$REGN $BIIB both looks ready for 2nd leg up. Added back on postioins from November

0 · Reply

RiskPulse_1667 Jan. 7 at 1:21 PM

$BIIB watching sector moves

0 · Reply

dogDazeSummer Jan. 6 at 9:45 PM

$VTYX in discussions with $LLY on oral anti inflammatory $1B deal 52 week low .84 52 week high $16.28, now https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2?st=77K3Z8&reflink=article_copyURL_share Can $IFRX catch a bid at JPM biotech conference? $AMGN $BIIB paid $1B and $4B Let’s go Niels, it’s been a long road, time for something sweeeeet ..

1 · Reply

JamesTate846 Jan. 6 at 5:27 PM

$FE $CQP $BIIB $AVB $SHG Nicely finalized

0 · Reply

Chartist0_0 Jan. 6 at 2:49 PM

$BIIB 250$ in March

0 · Reply

MoneyGroupLLC Jan. 6 at 11:36 AM

Enter: $BIIB Calls Strike Price: $178 Expiry Date: JAN 30 2026 Buy in Price: $6.00 - $6.30 Sell Price: $10.56 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Market Cap	27.52B
Revenue (ttm)	9.68B
Net Income (ttm)	1.63B
EPS (ttm)	N/A
PE Ratio	11.21
Forward PE	12.39
Profit Margin	16.87%
Debt to Equity Ratio	0.35

Volume	1,416,700
Avg Vol	2,113,484
Day's Range	N/A - N/A
Shares Out	146.70M
Stochastic %K	86%
Beta	0.13
Analysts	Sell
Price Target	$184.39